Clinical Trials
2 trialsNCT07311577 2025-12-31
Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
NCT04389229 2020-12-16
OVSTAR
Immetacyte Ltd
Phase 1/2 Withdrawn